top of page
April 16, 2025
Elusys Therapeutics Commends U.S. Congress for Introduction of H.R. 2707
Urges Swift Passage of H.R. 2707, the First Standalone Anthrax Preparedness Legislation in Over a Decade
April 16, 2025
Elusys Therapeutics Commends U.S. Congress for Introduction of H.R. 2707
Urges Swift Passage of H.R. 2707, the First Standalone Anthrax Preparedness Legislation in Over a Decade
December 4, 2024
Elusys Invited to Present LAV-BASTA-48 Anthrax Vaccine at the Annual DTRA Conference
Live Attenuated Single-Dose Spore-Based MDR-Anthrax Vaccine elicits protective immunity for postexposure Anthrax prophylaxis
December 4, 2024
Elusys Invited to Present LAV-BASTA-48 Anthrax Vaccine at the Annual DTRA Conference
Live Attenuated Single-Dose Spore-Based MDR-Anthrax Vaccine elicits protective immunity for postexposure Anthrax prophylaxis
April 27, 2022
Elusys Executes Initial Procurement Contract to Deliver ANTHIM® to the Canadian Government
New contract marks the first international sale of ANTHIM®
April 27, 2022
Elusys Executes Initial Procurement Contract to Deliver ANTHIM® to the Canadian Government
New contract marks the first international sale of ANTHIM®
News & Media
Newsletter Signup
Be the first to receive the latest news and updates.
bottom of page